Norwood Abbey Limited Presents Half-Year Results And Summary Of Operations

10/19/2005 5:12:53 PM

MELBOURNE, Australia--(BUSINESS WIRE)--March 1, 2005--Norwood Abbey Limited (Other-OTC:NABYF) (ASX:NAL): Highlights: -- Board of Directors re-structured with three U.S.-based appointments -- EyeCare infrastructure developed; sales/marketing program commences worldwide -- Laser Assisted Drug Delivery (LAD) pediatric hospital sales/marketing program continues -- Needle-free drug delivery product development progresses; chemical mulesing solution with Australian Wool Innovations Ltd. (AWI) a priority -- Immunology receives U.S. FDA acceptance of Investigational New Drug (IND) application for first U.S.-based clinical trial, supported by consortium of leading cancer specialists, co-funded by the U.S. National Cancer Institute and the National Institute of Allergy and Infectious Diseases

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Norwood Abbey Limited

• National Institute of Allergy And Infectious Diseases (NIAID)

• Biotech/Pharma - Earnings

• Clinical - IND